PHASQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHASQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
PhaseBio Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Jun. 2022 was $-2.64.
The industry rank for PhaseBio Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:
The historical data trend for PhaseBio Pharmaceuticals's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhaseBio Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
Net-Net Working Capital | Get a 7-Day Free Trial | -132.04 | 2.00 | 1.79 | -1.61 | -2.32 |
PhaseBio Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Net-Net Working Capital | Get a 7-Day Free Trial | -1.15 | -1.49 | -2.32 | -2.51 | -2.64 |
For the Biotechnology subindustry, PhaseBio Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where PhaseBio Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.
PhaseBio Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2021 is calculated as
Net-Net Working Capital | (A: Dec. 2021 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (41.8 | + | 0.75 * 0 | + | 0.5 * 0 | - | 153.574 |
- | 0 | - | 0) | / | 48.1906 | ||
= | -2.32 |
PhaseBio Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2022 is calculated as
Net-Net Working Capital | (Q: Jun. 2022 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (7.804 | + | 0.75 * 0 | + | 0.5 * 0 | - | 139.564 |
- | 0 | - | 0) | / | 49.8581 | ||
= | -2.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
PhaseBio Pharmaceuticals (OTCPK:PHASQ) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
New Enterprise Associates 13 Lp | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Glen Burkhardt | officer: VP, Human Resources | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355 |
Jonathan Birchall | officer: Chief Commercial Officer | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355 |
William D. Humphries | director | C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044 |
Clay Thorp | director | C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701 |
Nancy J Hutson | director | 64 MONTAUK AVENUE, STONINGTON CT 06378 |
Edmund Harrigan | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Caroline M Loewy | director | 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Van Den Broek Richard | director | 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
Peter Justin Klein | director | 5425 WISCONSIN AVE, CHEVY CHASE MD 20815 |
David James Ballance | officer: VP, Research and Sci. Affairs | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355 |
Michael York | officer: VP, Corporate Development | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355 |
John Sang Lee | officer: Chief Medical Officer | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355 |
Susan Elizabeth Arnold | officer: VP, Preclinical and Chem | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355 |
Kristopher Hanson | officer: VP, Head of Legal | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355 |
From GuruFocus
By Business Wire Business Wire • 08-10-2021
By Business Wire Business Wire • 12-21-2021
By Business Wire Business Wire • 05-13-2021
By Business Wire Business Wire • 05-16-2022
By Business Wire Business Wire • 05-20-2021
By Business Wire Business Wire • 08-12-2021
By Business Wire Business Wire • 03-11-2021
By Business Wire Business Wire • 11-15-2021
By Business Wire Business Wire • 06-17-2021
By GuruFocus Research GuruFocus Editor • 07-19-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.